首页 > 最新文献

American Journal of Medicine最新文献

英文 中文
Hepatic Artery Aneurysm. 肝动脉瘤。
IF 2.5 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-29 DOI: 10.1016/j.amjmed.2024.11.026
Chun-Ju Lien, Wan-Ching Lien
{"title":"Hepatic Artery Aneurysm.","authors":"Chun-Ju Lien, Wan-Ching Lien","doi":"10.1016/j.amjmed.2024.11.026","DOIUrl":"10.1016/j.amjmed.2024.11.026","url":null,"abstract":"","PeriodicalId":50807,"journal":{"name":"American Journal of Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142774322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Selection of Fascinating Facts About the Brain and Heart. 关于大脑和心脏的奇妙事实选集》。
IF 2.5 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-22 DOI: 10.1016/j.amjmed.2024.11.017
Joseph S Alpert
{"title":"A Selection of Fascinating Facts About the Brain and Heart.","authors":"Joseph S Alpert","doi":"10.1016/j.amjmed.2024.11.017","DOIUrl":"10.1016/j.amjmed.2024.11.017","url":null,"abstract":"","PeriodicalId":50807,"journal":{"name":"American Journal of Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142695972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Have You Ever Wondered? 你有没有想过?
IF 2.5 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-22 DOI: 10.1016/j.amjmed.2024.11.018
Joseph S Alpert
{"title":"Have You Ever Wondered?","authors":"Joseph S Alpert","doi":"10.1016/j.amjmed.2024.11.018","DOIUrl":"10.1016/j.amjmed.2024.11.018","url":null,"abstract":"","PeriodicalId":50807,"journal":{"name":"American Journal of Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142695973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Regarding a Randomized Controlled Trial on Allopurinol for Secondary Prevention of Cirrhosis-Related Complications 关于别嘌醇用于肝硬化相关并发症二级预防的随机对照试验。
IF 2.5 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-22 DOI: 10.1016/j.amjmed.2024.04.009
Mackenzie Balzan PharmD
{"title":"Regarding a Randomized Controlled Trial on Allopurinol for Secondary Prevention of Cirrhosis-Related Complications","authors":"Mackenzie Balzan PharmD","doi":"10.1016/j.amjmed.2024.04.009","DOIUrl":"10.1016/j.amjmed.2024.04.009","url":null,"abstract":"","PeriodicalId":50807,"journal":{"name":"American Journal of Medicine","volume":"137 12","pages":"Pages e240-e241"},"PeriodicalIF":2.5,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142695976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Link in the Chain. 链中的一环。
IF 2.5 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-20 DOI: 10.1016/j.amjmed.2024.11.016
Richard B Weinberg
{"title":"A Link in the Chain.","authors":"Richard B Weinberg","doi":"10.1016/j.amjmed.2024.11.016","DOIUrl":"10.1016/j.amjmed.2024.11.016","url":null,"abstract":"","PeriodicalId":50807,"journal":{"name":"American Journal of Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142689580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oral Rehydration Solution: A Landmark Discovery in Medicine and the Legacy of Dr. Dilip Mahalanabis. 口服补液:医学界的里程碑式发现和迪利普-马哈拉那比斯博士的遗产。
IF 2.5 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-20 DOI: 10.1016/j.amjmed.2024.10.045
Rupak Chatterjee, Atanu Chandra, Alex George, Sugata Dasgupta
{"title":"Oral Rehydration Solution: A Landmark Discovery in Medicine and the Legacy of Dr. Dilip Mahalanabis.","authors":"Rupak Chatterjee, Atanu Chandra, Alex George, Sugata Dasgupta","doi":"10.1016/j.amjmed.2024.10.045","DOIUrl":"10.1016/j.amjmed.2024.10.045","url":null,"abstract":"","PeriodicalId":50807,"journal":{"name":"American Journal of Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142689490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The $12 Billion Board Certification Process: Examination Characteristics, Revenues, and Expenditures. 价值 120 亿美元的委员会认证程序:考试特点、收入和支出。
IF 2.5 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-19 DOI: 10.1016/j.amjmed.2024.11.012
Manjot Singh, Brian McCrae, Joseph E Nassar, Michael J Farias, Ashley Knebel, Bassel G Diebo, Alan H Daniels

Background: Over 90% of U.S. physicians are currently board certified. Although the American Board of Medical Specialties (ABMS) has established standards for physicians to acquire and maintain board certification, a comprehensive description of this process and its associated costs has not been performed.

Methods: Population-level data of currently active diplomates was extracted from published ABMS reports. Examination characteristics of the initial and continuing certification process were extracted from each member board website. Revenue, expenditures, liabilities, and assets of each board for the latest tax year were extracted from published IRS Form 990s.

Results: Between 2016 to 2023, the number of physicians with active and continuous certification increased by 14% and 33%, respectively. Initial certification had a mean of 300 questions over 6 hours, an 89% pass rate, and a cost of $2,942. Continuous certification had a mean of 49 questions with 4 minutes per question, a 93% pass rate, and a cost of $263 annually. Total industry costs were estimated as $2,908,864,254 for initial certification and $9,101,324,085 for continuing certification. For the tax year 2022, this certification process generated $47 million in surplus and yielded $839 million net balance for all ABMS member boards.

Conclusions and relevance: ABMS board certification costs nearly $3 billion for initial certification and an additional $9 billion for continuing certification for currently practicing physicians over their careers. Ongoing research should evaluate the utility of the board certification system and explore ways to add value to this process.

背景:目前,超过 90% 的美国医生获得了委员会认证。尽管美国医学专科委员会(ABMS)已制定了医生获得和保持委员会认证的标准,但尚未对这一过程及其相关成本进行全面描述:方法:从公布的 ABMS 报告中提取了目前在职认证医师的人口级数据。从各成员委员会的网站上提取了初始认证和继续认证过程的考试特征。从公布的美国国税局990表格中提取了每个委员会最近纳税年度的收入、支出、负债和资产:从 2016 年到 2023 年,获得有效认证和持续认证的医生人数分别增加了 14% 和 33%。初次认证的平均问题数为 300 个,耗时 6 小时,通过率为 89%,费用为 2942 美元。持续认证的平均问题数为 49 个,每个问题耗时 4 分钟,通过率为 93%,每年费用为 263 美元。据估算,初始认证的行业总成本为 2,908,864,254 美元,持续认证的行业总成本为 9,101,324,085 美元。在2022纳税年度,该认证过程产生了4700万美元的盈余,并为所有ABMS成员委员会带来了8.39亿美元的净余额:ABMS 委员会认证的初始认证费用近 30 亿美元,目前执业医师在其职业生涯中的继续认证费用为 90 亿美元。正在进行的研究应评估委员会认证系统的效用,并探索增加这一过程价值的方法。
{"title":"The $12 Billion Board Certification Process: Examination Characteristics, Revenues, and Expenditures.","authors":"Manjot Singh, Brian McCrae, Joseph E Nassar, Michael J Farias, Ashley Knebel, Bassel G Diebo, Alan H Daniels","doi":"10.1016/j.amjmed.2024.11.012","DOIUrl":"10.1016/j.amjmed.2024.11.012","url":null,"abstract":"<p><strong>Background: </strong>Over 90% of U.S. physicians are currently board certified. Although the American Board of Medical Specialties (ABMS) has established standards for physicians to acquire and maintain board certification, a comprehensive description of this process and its associated costs has not been performed.</p><p><strong>Methods: </strong>Population-level data of currently active diplomates was extracted from published ABMS reports. Examination characteristics of the initial and continuing certification process were extracted from each member board website. Revenue, expenditures, liabilities, and assets of each board for the latest tax year were extracted from published IRS Form 990s.</p><p><strong>Results: </strong>Between 2016 to 2023, the number of physicians with active and continuous certification increased by 14% and 33%, respectively. Initial certification had a mean of 300 questions over 6 hours, an 89% pass rate, and a cost of $2,942. Continuous certification had a mean of 49 questions with 4 minutes per question, a 93% pass rate, and a cost of $263 annually. Total industry costs were estimated as $2,908,864,254 for initial certification and $9,101,324,085 for continuing certification. For the tax year 2022, this certification process generated $47 million in surplus and yielded $839 million net balance for all ABMS member boards.</p><p><strong>Conclusions and relevance: </strong>ABMS board certification costs nearly $3 billion for initial certification and an additional $9 billion for continuing certification for currently practicing physicians over their careers. Ongoing research should evaluate the utility of the board certification system and explore ways to add value to this process.</p>","PeriodicalId":50807,"journal":{"name":"American Journal of Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142683338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effectiveness of Single Versus Multiple Inhaler Triple Therapy on Mortality and Cardiopulmonary Risk Reduction in COPD: The SKOPOS-MAZI Study. 单吸入器与多吸入器三联疗法对降低慢性阻塞性肺病死亡率和心肺风险的效果:SKOPOS-MAZI 研究。
IF 2.5 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-18 DOI: 10.1016/j.amjmed.2024.11.007
Michael Pollack, Eleni Rapsomaniki, Antonio Anzueto, Kirsty Rhodes, Nathaniel M Hawkins, Claus F Vogelmeier, Jonathan Marshall, Hana Müllerová

Background: Patients with chronic obstructive pulmonary disease (COPD) have elevated cardiopulmonary and mortality risk, particularly following exacerbations. While single inhaler triple therapies (SITTs), such as budesonide/glycopyrrolate/formoterol fumarate (BGF), reduce cardiopulmonary risk versus dual bronchodilator therapy, there is limited evidence comparing outcomes with SITTs versus multiple inhaler triple therapies (MITTs).

Methods: SKOPOS-MAZI was a retrospective comparative effectiveness study in patients with COPD aged ≥40 years using US administrative claims data from Optum's deidentified Clinformatics® Data Mart Database. The primary and secondary endpoints were time to all-cause mortality and time to first severe cardiopulmonary event following initiation of BGF or MITT (identification period: October 1, 2020-June 30, 2023; index date: first prescription fill). Relative hazards of outcomes were assessed until a censoring event using Cox proportional hazards models, with inverse propensity treatment weighting accounting for between-group imbalances (standardized mean difference >0.1) in baseline characteristics.

Results: In the primary cohort, risk (hazard ratio [95% confidence intervals]) of all-cause mortality and a first severe cardiopulmonary event were 18% (0.82 [0.75, 0.91]) and 12% (0.88 [0.83, 0.93]) lower in patients initiating BGF versus MITT; results were consistent across censoring definitions, landmark periods, and sensitivity cohorts.

Conclusion: In this real-world comparative effectiveness study of patients with COPD initiating BGF or MITT, BGF was associated with lower all-cause mortality and severe cardiopulmonary event risk versus MITT after accounting for between-group differences in baseline sociodemographic and clinical characteristics. This study supports the benefits of BGF over MITT and the need to consider proactive use of SITTs in COPD management.

背景:慢性阻塞性肺病(COPD)患者的心肺功能和死亡风险较高,尤其是在病情加重后。布地奈德/甘草酸苷/富马酸福莫特罗(BGF)等单吸入器三联疗法(SITTs)与双支气管扩张剂疗法相比可降低心肺风险,但比较单吸入器三联疗法与多吸入器三联疗法(MITTs)疗效的证据却很有限:SKOPOS-MAZI是一项回顾性疗效比较研究,研究对象是年龄≥40岁的慢性阻塞性肺病患者,研究使用了Optum去标识化Clinformatics®数据集市数据库中的美国行政索赔数据。主要和次要终点是开始使用 BGF 或 MITT 后的全因死亡时间和首次严重心肺事件发生时间(识别期:2020 年 10 月 1 日至 6 月 30 日):识别期:2020 年 10 月 1 日至 2023 年 6 月 30 日;指标日期:首次开具处方)。使用 Cox 比例危险度模型评估结果的相对危险度,直至发生剔除事件,并采用逆倾向治疗加权法考虑组间基线特征的不平衡(标准化平均差大于 0.1):在主要队列中,开始接受 BGF 治疗的患者与接受 MITT 治疗的患者相比,全因死亡率和首次严重心肺事件的风险(危险比 [95% 置信区间])分别降低了 18% (0.82 [0.75, 0.91])和 12% (0.88 [0.83, 0.93]);在不同的剔除定义、标志性时期和敏感性队列中,结果是一致的:在这项针对开始使用 BGF 或 MITT 的慢性阻塞性肺病患者的真实世界比较有效性研究中,在考虑了基线社会人口学和临床特征的组间差异后,BGF 与 MITT 相比,具有更低的全因死亡率和严重心肺事件风险,这支持了 BGF 优于 MITT 的益处,以及在慢性阻塞性肺病管理中考虑积极使用 SITT 的必要性。
{"title":"Effectiveness of Single Versus Multiple Inhaler Triple Therapy on Mortality and Cardiopulmonary Risk Reduction in COPD: The SKOPOS-MAZI Study.","authors":"Michael Pollack, Eleni Rapsomaniki, Antonio Anzueto, Kirsty Rhodes, Nathaniel M Hawkins, Claus F Vogelmeier, Jonathan Marshall, Hana Müllerová","doi":"10.1016/j.amjmed.2024.11.007","DOIUrl":"10.1016/j.amjmed.2024.11.007","url":null,"abstract":"<p><strong>Background: </strong>Patients with chronic obstructive pulmonary disease (COPD) have elevated cardiopulmonary and mortality risk, particularly following exacerbations. While single inhaler triple therapies (SITTs), such as budesonide/glycopyrrolate/formoterol fumarate (BGF), reduce cardiopulmonary risk versus dual bronchodilator therapy, there is limited evidence comparing outcomes with SITTs versus multiple inhaler triple therapies (MITTs).</p><p><strong>Methods: </strong>SKOPOS-MAZI was a retrospective comparative effectiveness study in patients with COPD aged ≥40 years using US administrative claims data from Optum's deidentified Clinformatics® Data Mart Database. The primary and secondary endpoints were time to all-cause mortality and time to first severe cardiopulmonary event following initiation of BGF or MITT (identification period: October 1, 2020-June 30, 2023; index date: first prescription fill). Relative hazards of outcomes were assessed until a censoring event using Cox proportional hazards models, with inverse propensity treatment weighting accounting for between-group imbalances (standardized mean difference >0.1) in baseline characteristics.</p><p><strong>Results: </strong>In the primary cohort, risk (hazard ratio [95% confidence intervals]) of all-cause mortality and a first severe cardiopulmonary event were 18% (0.82 [0.75, 0.91]) and 12% (0.88 [0.83, 0.93]) lower in patients initiating BGF versus MITT; results were consistent across censoring definitions, landmark periods, and sensitivity cohorts.</p><p><strong>Conclusion: </strong>In this real-world comparative effectiveness study of patients with COPD initiating BGF or MITT, BGF was associated with lower all-cause mortality and severe cardiopulmonary event risk versus MITT after accounting for between-group differences in baseline sociodemographic and clinical characteristics. This study supports the benefits of BGF over MITT and the need to consider proactive use of SITTs in COPD management.</p>","PeriodicalId":50807,"journal":{"name":"American Journal of Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142683326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Physical Therapy for Patients with Thoracolumbar Vertebral Fractures. 胸腰椎骨折患者的物理治疗。
IF 2.5 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-17 DOI: 10.1016/j.amjmed.2024.11.005
Andrew Y Xu, Krish Shah, Manjot Singh, Joseph E Nassar, Jinho Kim, Yatharth Sharma, Michael J Farias, Bassel G Diebo, Alan H Daniels

Vertebral fractures are a common cause of back pain and pain-related functional impairments in elderly patients. Despite their widespread occurrence, vertebral fractures frequently remain underdiagnosed, often leading to suboptimal management and poor clinical outcomes. This review specifically examines the role of physical therapy (PT) in managing vertebral fractures, describing current literature and evidence-based guidelines from the American Physical Therapy Association and the American Academy of Orthopaedic Surgeons. PT following vertebral fractures has been shown to significantly improve back pain and patient-reported outcomes, with studies even showing a correlation between resistance and aerobic training with improved bone mineral density. These findings highlight the need for interdisciplinary care and comprehensive PT interventions to address the growing burden of vertebral fractures as their incidence rises with the aging population.

椎体骨折是导致老年患者背部疼痛和与疼痛相关的功能障碍的常见原因。尽管椎体骨折的发生率很高,但往往诊断不足,导致治疗效果不佳,临床疗效不佳。本综述特别探讨了物理治疗(PT)在椎体骨折管理中的作用,介绍了美国物理治疗协会和美国骨科外科医生学会的现有文献和循证指南。研究表明,椎体骨折后的物理治疗可显著改善背痛和患者报告的结果,研究甚至显示阻力训练和有氧训练与骨矿物质密度改善之间存在相关性。这些研究结果突出表明,随着人口老龄化的加剧,椎体骨折的发病率也在不断上升,因此需要进行跨学科护理和全面的运动疗法干预,以解决椎体骨折带来的日益沉重的负担。
{"title":"Physical Therapy for Patients with Thoracolumbar Vertebral Fractures.","authors":"Andrew Y Xu, Krish Shah, Manjot Singh, Joseph E Nassar, Jinho Kim, Yatharth Sharma, Michael J Farias, Bassel G Diebo, Alan H Daniels","doi":"10.1016/j.amjmed.2024.11.005","DOIUrl":"10.1016/j.amjmed.2024.11.005","url":null,"abstract":"<p><p>Vertebral fractures are a common cause of back pain and pain-related functional impairments in elderly patients. Despite their widespread occurrence, vertebral fractures frequently remain underdiagnosed, often leading to suboptimal management and poor clinical outcomes. This review specifically examines the role of physical therapy (PT) in managing vertebral fractures, describing current literature and evidence-based guidelines from the American Physical Therapy Association and the American Academy of Orthopaedic Surgeons. PT following vertebral fractures has been shown to significantly improve back pain and patient-reported outcomes, with studies even showing a correlation between resistance and aerobic training with improved bone mineral density. These findings highlight the need for interdisciplinary care and comprehensive PT interventions to address the growing burden of vertebral fractures as their incidence rises with the aging population.</p>","PeriodicalId":50807,"journal":{"name":"American Journal of Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2024-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142669959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Primary Breast Diffuse Large B-Cell Lymphoma in an Immunocompetent Male. 免疫功能正常男性的原发性乳腺弥漫性大 B 细胞淋巴瘤
IF 2.5 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-17 DOI: 10.1016/j.amjmed.2024.11.009
Christopher Mikulas, Kevin Parza, Matthew Carpenter, Ahmad Alkhasawneh, Reeba Prince, W Jr Quan
{"title":"Primary Breast Diffuse Large B-Cell Lymphoma in an Immunocompetent Male.","authors":"Christopher Mikulas, Kevin Parza, Matthew Carpenter, Ahmad Alkhasawneh, Reeba Prince, W Jr Quan","doi":"10.1016/j.amjmed.2024.11.009","DOIUrl":"10.1016/j.amjmed.2024.11.009","url":null,"abstract":"","PeriodicalId":50807,"journal":{"name":"American Journal of Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2024-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142649709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
American Journal of Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1